dc.contributor.author
Sicras Mainar, Antoni
dc.contributor.author
Rejas, Javier
dc.contributor.author
Pérez-Paramo, Maria
dc.contributor.author
Sánchez-Álvarez, Luis
dc.contributor.author
Navarro-Artieda, Ruth
dc.contributor.author
Darbà, Josep
dc.date.issued
2019-05-24T07:41:51Z
dc.date.issued
2020-02-28T06:10:17Z
dc.date.issued
2019-05-24T07:41:51Z
dc.identifier
https://hdl.handle.net/2445/133837
dc.description.abstract
Background: Discrepancies are seen between arguments in favor of and against prescribing generic versus brand-name drugs. Objective: To provide real-world evidence on treatment persistence, economic and clinical outcomes of pregabalin, generic versus brand-name (Lyrica®, Pfizer), routinely used to treat neuropathic pain (NP) or generalized anxiety disorder (GAD). Methods: Electronic medical records from subjects' first starting treatment with pregabalin between January-2015 and June-2016 were analyzed. Persistence, resources utilization, and costs were assessed, along with remitter and responder rates. (...)
dc.format
application/pdf
dc.publisher
Informa Healthcare
dc.relation
Versió postprint del document publicat a: https://doi.org/10.1080/14737167.2019.1519399
dc.relation
Expert Review of Pharmacoeconomics & Outcomes Research, 2019, vol. 19, num. 1, p. 45-57
dc.relation
https://doi.org/10.1080/14737167.2019.1519399
dc.rights
(c) Informa Healthcare, 2019
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Economia)
dc.subject
Medicaments genèrics
dc.subject
Anàlisi cost-benefici
dc.subject
Neuropsicofarmacologia
dc.subject
Tractament del dolor
dc.subject
Cost effectiveness
dc.subject
Neuropsychopharmacology
dc.subject
Pain treatment
dc.title
Consequences on economic outcomes of generic versus brand-name drugs used in routine clinical practice: the case of treating peripheral neuropathic pain or generalized anxiety disorder with pregabalin
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/acceptedVersion
